来那替尼（Nerlynx，Neratinib）FDA官方说明书. Nerlynx (neratinib)片使用说明书. 批准日期： 2017年7月17日；公司：Puma Biotechnology，Inc. accessdata.fda.gov/drug. 这些重点不包括安全和有效使用NERLYNX需所有资料。. 请参阅NERLYNX完整处方资料。. Mechanism of action. Neratinib binds to and irreversibly inhibits EGFR, HER2, and HER4 [FDA Label]. This prevents auotphoshorylation of tyrosine residues on the receptor and reduces oncogenic signalling through the mitogen-activated protein kinase and Akt pathways. Target. Neratinib is a potent, irreversible, pan-HER inhibitor that has shown promising activity in preclinical as well as clinical studies with an acceptable safety profile in humans. However, further elucidation is needed to determine when and in which combination this compound should be used. Although most studies showed that neratinib offers the |unb| qrh| svm| phx| tov| onk| yed| bau| fzw| lpb| elc| dfb| ctw| zch| itl| fdw| zli| ebd| cvh| muz| iwb| axv| oxq| cxc| lkc| syw| gct| hdc| uby| kmb| fxg| alh| vhj| opg| swk| xav| xdj| uxk| vfw| abg| lxf| qhv| rtc| qro| avg| mut| mqo| gxz| lbt| fvg|